ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2615

Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis

Tatiana Nevskaya 1, Yuxuan Jiang 1, Mianbo Wang 2 and Janet Pope3, 1University of Western Ontario, London, ON, Canada, 2Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, 3Western University, London, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: epidemiologic methods and outcomes, Pulmonary Involvement, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc), thought to be more commonly found among the limited cutaneous (lcSSc) compared to diffuse (dcSSc) disease subtype. Since lcSSc is associated with better prognosis, it is unclear whether a higher occurrence of PAH in lcSSc is a reflection of survival bias, especially when longer disease duration and older age increase the risk of PAH. We assessed survival and incidence of PAH, after accounting for death as competing event, in a large multi-center cohort of SSc patients, and explored predictors of PAH development and survival.

Methods: The study consisted of 1689 SSc patients from Canadian Scleroderma Research Group registry, followed for up to 14 years. To compare cumulative incidence between disease subsets, a competing risk analysis (Fine-Gray model with death as competing event) unadjusted and adjusted for sex, age and SSc-related autoantibodies was performed (SAS 9.4). Survival was analyzed by Kaplan-Meier with Log-Rank (Mantel Cox) test; Cox proportional hazards analysis with demographic, clinical, and laboratory characteristics as predictor variables was used to develop prediction models for PH (SPSS 25.0).

Results: Out of 1431 patients (43% dcSSc, 57% lcSSc, mean age at SSc diagnosis 48±13, follow up 3.5±2.9 yrs., range 1-14 yrs.) with sufficient data for PAH, 157 patients had PAH either confirmed by RHC or post mortem. Regardless of SSc subtype, patients with PAH had more severe disease (by HAQ-DI and patient’s global assessment of health) and higher mortality (74% vs 11%, p< 0.0001), compared to those without PAH (Table 1). The lcSSc patients with PAH were older at SSc diagnosis and had a longer disease duration from Raynaud’s phenomenon (RP), compared to lcSSc without PAH. The dcSSc patients with PAH had more severe peripheral vascular (SHAQ RP and finger ulcers) and gastrointestinal (SHAQ intestinal problems) vs dcSSc without PAH. 47% of patients with PAH died: 45 lcSSc and 29 dcSSc. Male gender and anti-Scl70 were associated with earlier development of PAH from both SSc diagnosis (p< 0.0001 and p=0.002, respectively) and first non-RP symptom (p< 0.0001 and p=0.001, respectively).To avoid left-censoring problem, 113 pts with PAH diagnosed at or before baseline registry visit were excluded from the cumulative incidence and survival analyses. Cumulative incidence of PAH from the onset of first non-RP symptom was higher in dcSSc than in lcSSc after accounting for death as competing event in unadjusted, but not adjusted competing risk analysis (see Table 2 and Figure). Survival (mean±SE) from PAH onset was similar in lcSSc and dcSSc (44±8 mo vs 38±7 mo, p=0.59).

Conclusion: Cumulative incidence of PAH from the onset of first non-Raynaud’s phenomenon symptom was not higher in lcSSc, after accounting for death as competing event and adjusting for age, sex and antibody status. Males and a-Scl-70-positive patients developed PAH earlier


Image for abstract

Cumulative incidence curve for PAH development in SSc subtypes


Table 1 for abstract

Table 1.Characteristics of patients with and without PAH in the entire SSc cohort, as well as separately in dcSSc and lcSSc sub-groups.


Table 2 for abstract

Table 2. Sub-distribution Hazard ratio of PAH by Fine-Gray model accounting for death as competing event


Disclosure: T. Nevskaya, None; Y. Jiang, None; M. Wang, None; J. Pope, AbbVie, 5, Abbvie, 5, Actelion, 5, Actellion, 5, Amgen, 2, 5, AstraZeneca, 2, Astra-Zeneca, 2, Bayer, 2, 5, BMS, 2, 5, Eicos Sciences, 5, Eli Lilly & Company, 5, Eli Lilly and Company, 5, EMERALD, 5, Emerald, 5, Genzyme, 5, Janssen, 5, Lilly, 5, Merck, 2, 5, Novartis, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 5, Sanofi, 5, Seattle Genetics, 2, UCB, 2, 5, 8.

To cite this abstract in AMA style:

Nevskaya T, Jiang Y, Wang M, Pope J. Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cumulative-incidence-survival-and-predictors-of-pulmonary-arterial-hypertension-in-disease-subsets-of-systemic-sclerosis-pah-is-not-increased-in-limited-vs-diffuse-patients-by-adjusted-competing-ris/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cumulative-incidence-survival-and-predictors-of-pulmonary-arterial-hypertension-in-disease-subsets-of-systemic-sclerosis-pah-is-not-increased-in-limited-vs-diffuse-patients-by-adjusted-competing-ris/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology